scholarly journals Advanced Parkinson’s Disease In Stockholm County, Sweden – How Many Are They And What Are The Real-Life Health Care Costs?

2016 ◽  
Vol 19 (7) ◽  
pp. A351-A352
Author(s):  
JK Eriksson ◽  
B Anell
Keyword(s):  
Parkinson’S Disease ◽  
Health Care ◽  
Parkinson's Disease ◽  
Health Care Costs ◽  
Real Life ◽  
Stockholm County ◽  
Advanced Parkinson’S Disease ◽  
The Real ◽  
Care Costs

Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population

2020 ◽  
Author(s):  
Nabila Dahodwala ◽  
Pengxiang Li ◽  
Jordan Jahnke ◽  
Vrushabh P. Ladage ◽  
Amy R. Pettit ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Health Care ◽  
Parkinson's Disease ◽  
Health Care Costs ◽  
Medicare Population ◽  
Care Costs ◽  
The U.S

scholarly journals Relationship between Adherence Level to Statins, Clinical Issues and Health-Care Costs in Real-Life Clinical Setting

2010 ◽  
Vol 13 (1) ◽  
pp. 87-94 ◽  
Author(s):  
Alice Dragomir ◽  
Robert Côté ◽  
Michel White ◽  
Lyne Lalonde ◽  
Lucie Blais ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Costs ◽  
Clinical Setting ◽  
Real Life ◽  
Adherence Level ◽  
Clinical Issues ◽  
Care Costs

scholarly journals Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs

2021 ◽  
Vol 5 (17) ◽  
pp. 3344-3353
Author(s):  
Abdülkadir Erçalışkan ◽  
Duygu Seyhan Erdoğan ◽  
Ahmet Emre Eşkazan
Keyword(s):  
Health Care ◽  
Health Care Costs ◽  
Financial Burden ◽  
Real Life ◽  
In Vivo Studies ◽  
Current Evidence ◽  
Efficacy And Safety ◽  
Alternative Treatment Option ◽  
The Impact ◽  
Care Costs

Abstract Since the introduction of imatinib, the management of chronic myeloid leukemia (CML) has changed considerably. Tyrosine kinase inhibitors (TKIs) are the mainstay of CML treatment; however, the high financial burden of TKIs can be problematic for both the patients and health care systems. After the emergence of generics, reimbursement policies of many countries have changed, and generics offered an alternative treatment option for CML patients. There are many papers published on the use of generics in CML patients with conflicting results regarding both efficacy and safety. In this paper, we systematically reviewed the current literature on generic imatinib use in CML, and 36 papers were evaluated. Both in vitro and in vivo studies of generic imatinib showed comparable results with branded imatinib in terms of bioequivalence and bioavailability. In most studies, generics were comparable with the original molecule in terms of efficacy and safety, both in newly diagnosed patients and after switching from Gleevec. Some generic studies showed contradictory findings regarding efficacy and toxicity, and these differences can be attributed to some factors including the use of different generics in different countries. Both in hypothetical models and in real life, introduction of generic imatinib caused significant reduction in health care costs. In conclusion, generics are not inferior to original imatinib in terms of efficacy with an acceptable toxicity profile. Notwithstanding the generally favorable efficacy and safety of generics worldwide to date, we most probably still need more time to draw firmer conclusions on the longer-term outcomes of generics.

scholarly journals Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Oliver Reich ◽  
Martin K. Schmid ◽  
Roland Rapold ◽  
Lucas M. Bachmann ◽  
Eva Blozik
Keyword(s):  
Health Care ◽  
Health Care Costs ◽  
Real Life ◽  
Care Costs

Dyadic Decision-Making in Advanced Parkinson’s Disease: A Mixed Methods Study

2019 ◽  
Vol 42 (5) ◽  
pp. 348-355 ◽  
Author(s):  
Barbara Habermann ◽  
Ju Young Shin ◽  
Gretchen Shearer
Keyword(s):  
Parkinson’S Disease ◽  
Health Care ◽  
Decision Making ◽  
Parkinson's Disease ◽  
Mixed Methods ◽  
Health Care Providers ◽  
Assisted Living ◽  
Decision Quality ◽  
Care Providers ◽  
Advanced Parkinson’S Disease

People with advanced Parkinson’s disease (PD) are living at home being cared for by a family member. Decisions about health care and living preferences are made in a family context. The aims of the study were to (a) examine the types and timing of the decisions being made by dyads (person with Parkinson’s [PWP] and caregiver) in advanced PD; and (b) explore perceived decision quality relative to specific decisions made. A mixed methods design of semi-structured dyad interviews followed by individual completion of decision measures twice at six months apart was utilized. Decisions involved obtaining more services in the home, moving into assisted living communities, maintaining as is, and initiating hospice. There was high decision quality as reflected by low decisional conflict and regret without statistical differences within the dyad. The findings provide insight into the nature of decisions dyads face and suggest ways that health care providers can support decision-making.

Sign in / Sign up

Export Citation Format

Share Document